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Since the discovery of circulating microRNAs (miRNAs) in body fluids, an increasing number of studies have focused
on their potential as non-invasive biomarkers and as therapeutic targets or tools for many diseases, particularly for
cancers. Because of their stability, miRNAs are easily detectable in body fluids. Extracellular miRNAs have potential
as biomarkers for the prediction and prognosis of cancer. Moreover, they also enable communication between cells
within the tumor microenvironment, thereby influencing tumorigenesis. In this review, we summarize the progresses
made over the past decade regarding circulating miRNAs, from the development of detection methods to their clinical
application as biomarkers and therapeutic tools for cancer. We also discuss the advantages and limitations of different
detection methods and the pathways of circulating miRNAs in cell-cell communication, in addition to their clinical
pharmacokinetics and toxicity in human organs. Finally, we highlight the potential of circulating miRNAs in clinical
applications for cancer.Introduction
MiRNAs are a class of small, single-stranded non-coding
RNAs of 19–24 nt in length that primarily function at
the posttranscriptional level [1-4]. MiRNAs function in
many biological processes, such as stem cell differenti-
ation, cell proliferation, cell apoptosis, and embryonic
development [5-7]. The majority of miRNAs appear to
be tissue-specific, and aberrant expression of miRNAs is
associated with many diseases including cancer [8-10].
Previous studies have demonstrated that miRNAs are
stable in serum and plasma and that their expression
profile responds to changes under different physiological
and pathological conditions [11,12]. Although circulating
miRNAs may serve as biomarkers for various types of
cancers [12-14], the isolation and measurement of circu-
lating miRNAs remains a challenging task. In addition,
although many studies have attempted to explain the
origin and function of circulating miRNAs in cancer
patients, no definitive source for these molecules has
been proposed. Some cell-free miRNAs in body fluids
may be packaged in exosomes, microvesicles or RNA-
binding-proteins, which provide protection from RNases
[15-19], and enable their transfer from one cell to* Correspondence: lsscyq@mail.sysu.edu.cn
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article, unless otherwise stated.another during diverse biological processes. By defining
tumors as relatively homogeneous cancer cells formed in
an independent microenvironment, circulating miRNAs
may play a novel role as regulators of cell-cell communi-
cations during cancer formation [20,21].
In this review, we summarize recent progress made in
understanding the role of circulating miRNAs in cancer,
including the application of different detection methods
and the quantification of serum miRNAs as non-invasive
biomarkers for cancer diagnostics. We also discuss impli-
cations for serum miRNAs in cell-to-cell communication
and review their roles in the development and progression
of cancer and in cancer therapy.
Detection methods to quantify serum miRNAs in cancer
patients
Although a number of studies have reported that miRNAs
are stable in serum and plasma and that their expression
profiles change under different physiological and patho-
logical conditions, their low enrichment in serum and the
isolation and quantification of circulating miRNAs is one of
the major issues in investigating circulating miRNAs. Cur-
rently, two major global miRNA profiling platforms have
been suggested: microarrays and quantitative polymerase
chain reaction (qPCR) based methods including relative
quantification RT-PCR [14,22,23] and absolute quantitative
PCR [24-26]. The methods used were shown in Table 1.ntral Ltd.; This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Summary of the circulating miRNAs that may be used as non-invasive biomarkers for the detection of cancer
Circulating miRNA Types of cancer Methods Source References
miR-155,-210,-21 Diffuse large B-cell lymphoma qRT-PCR serum [14]
miR-132, -181c, -15a, -370,
-143-3p, -21-5p, -200a-3p, -646
Cervical squamous cell carcinoma TaqMan miRNA array, qRT-PCR serum [26]
miR-122 Chronic hepatitis B Microarray, qRT-PCR serum [28]
miR-141 Prostate cancer qRT-PCR serum/plasma [29,41]
miR-1233 Renal cell carcinoma TaqMan low density array, qRT-PCR serum [30]
mir-16,-25 Multiple myeloma NanoString-nCounter
microRNA assays
serum [31,52]
miR-17, -20a, -29c, -223 Nasopharyngeal carcinoma Microarray, qRT-PCR serum [32]
miR-17-3p, -29a, -92a, -221 Colorectal Cancer qRT-PCR serum [41,42,51]
miR-155 Breast Cancer TaqMan miRNA array, qRT-PCR serum [41,49,54]
miR-21, -26a, -27a, -122, -192, -223, -801 Hepatocellular cancer Microarray, qRT-PCR serum [48]
miR-16, -25, -92a, -451, miR-486-5p Gastric non-cardia adenocarcinoma TaqMan low density array, qRT-PCR serum [50]
miR-425-5p, -93-5p Head and neck cancer qRT-PCR Plasma [53]
miR-122 Chronic hepatitis C qRT-PCR serum [55]
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quantification RT-PCR, which has been widely used. This
method can be used to detect miRNAs from either tissue
samples or serum samples [22,24,27]. However, this
method requires a suitable internal control, and some re-
searchers have noted that internal controls, such as U6
[28], UNR6B [23], miR-16 [29] and miR-39 [30], are not
stable or reliable. For example, circulating miR-16 can
serve as an internal control in prostate cancer [29] but it
is dysregulated in multiple myeloma [31] and early
rheumatoid arthritis [32], thus indicating that the use of
internal controls for serum requires carefully planning. To
overcome this problem, some studies have suggested add-
ing an external control to normalize the level of circulat-
ing miRNAs. The exogenous references that have been
used are non-human mature miRNAs, such as cel-miR-39
[33], cel-miR-54 [26] and cel-miR-238 [34], which are
spiked into the serum samples prior to RNA extraction.
However, it is difficult control the amount of this artifi-
cial external control added into different serum samples.
Because of the difficulties regarding endogenous controls,
absolute quantitative PCR was developed. This method
can be used to measure circulating miRNA expression in-
dependently, and the CT value does not require normaliz-
ing using endogenous or external controls, such as U6 or
housekeeping miRNAs [35,36]. However, this method also
has disadvantages; for example, the standard curve for ab-
solute quantitative PCR for specific miRNAs must be ini-
tially constructed using a series of standards, which is
labor-intensive, time-consuming and relatively costly.
In recent years, microarray-based techniques have also
been widely used to detect expression profiles of circulating
miRNAs [25,26,30-32,37]. The advantage of the microarray
method is its ability to assess genome-wide expressionprofiles of miRNAs in body fluids and to provide large
amounts of candidate biomarkers for diagnostic purposes
in cancer. However, this method requires a large amount of
total RNA and a pre-amplification step, which may be risk
of changing the original concentration of the circulating
miRNAs. Chen et al. quantified circulating miRNA expres-
sion using both RT-PCR and microarray and noted a weak
correlation [38], implying a risk of inaccuracy when using
microarray-based methods.
In addition to the methods mentioned above, new
methodologies for measuring circulating miRNAs have
emerged recently. Ho and colleagues developed a self-
assembling protein platform for the direct quantification
of circulating miRNAs in serum based on total internal
reflection fluorescence microscopy; a direct, specific and
highly sensitive yet simple detection assay for miRNA
that does not require sample amplification [39]. Using a
self-assembled protein nanofibril and a locked nucleic
acid (LNA) as the complimentary sequence and probe to
capture the target miRNAs, this method can detect very
low concentrations of RNA. A detection limit of 1 pM
was achieved using trace amounts of sample [39]. Lusi
et al. also developed a PCR- and label-free method to
detect miRNA based on an electrochemical genosensor
with a detection limit of up to 0.1 pmol [40,41]. Currently,
some commercial PCR kits can directly detect RNA in
serum or other body fluids without RNA isolation [42],
which might be an important trend in circulating DNA
and RNA detection, particularly for circulating miRNAs.
Finally, it is worth mentioning that following the emer-
gence of next-generation sequencing (NGS), NGS has
been widely used in detecting circulating miRNAs and for
the identification of novel miRNAs [43-47]. This tech-
nique does not rely on probes specific to each miRNA and
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hensive and accurate measurements of miRNAs [43,44];
however, its disadvantages are that it is expensive and
resource-consuming.
Based on the discussion above, it could be suggested
that the quality of RNA is one of the most important
issues for measuring circulating miRNAs. On a different
note, circulating miRNAs are easily contaminated by serum
cellular components, such as platelets or erythrocytes, and
must be very carefully centrifuged from serum or other
body fluids. This point is particularly important in the case
of microarray assays. Another key issue is RNA purity and
integrity, which may improve the accuracy of detection.
Implications of circulating miRNAs as biomarkers for cancer
Circulating miRNAs have numerous advantages including
stably existing in almost all body fluids, cancer-specific or
tightly correlating with physiological and pathological
changes and easily detectable. Consequently, a number of
studies have proposed that circulating miRNAs could
be ideal biomarkers for the prediction and prognosis of
cancer. The first comprehensive analysis of circulating
miRNAs in cancer patients was performed by Lawrie
et al. They compared the expression levels of tumor-
associated miR-155, miR-210 and miR-21 in serum
from patients with diffuse large B-cell lymphoma with
levels in serum from healthy controls and observed
higher levels in patients compared with controls [14].
Mitchell et al. established an important approach when
measuring tumor-derived miRNAs in serum or plasma
and suggested that serum level of miR-141 can distinguish
patients with prostate cancer from healthy controls
[29]. In hepatocellular cancer, based on microarray and
qRT-PCR, seven circulating miRNAs (miR-21, -26a,
-27a, -122, -192, -223, and -801) were reported to dif-
ferentiate HCC patients from healthy controls, patients
with chronic hepatitis B or patients with cirrhosis [48].
Table 1 summarizes recently described circulating miRNAs
that may be used as non-invasive biomarkers for cancer
detection.
In further examples of the differentiation of diseased
patients from healthy controls, circulating miRNAs have
also been demonstrated as biomarkers for early-stage
cancer diagnosis. For example, Roth et al. noted that the
concentration of miR-155 in serum significantly discrim-
inated M0- breast cancer patients from healthy women
[49]. Zhu et al. also identified five miRNAs (miR-16,
miR-25, miR-92a, miR-451 and miR-486-5p) as potential
markers for the early-stage gastric non-cardia adenocar-
cinoma (GNCA) (stage I) [50]. It has been reported that
circulating miR-92a was dysregulated in non-metastatic
and metastatic colorectal cancer (CRC) patients and
showed potential as a non-invasive biomarker for the
early detection of liver metastasis in CRC patients [51].More importantly, clinical studies have also demonstrated
the potential use of miRNAs as promising biomarkers
for assessing cancer prognosis. Rocci A et al. used the
International Staging System (ISS) and the presence or
absence of specific fluorescent in-situ hybridization ab-
normalities to test circulating miRNAs in patients with
multiple myeloma (MM) and suggested that circulating
miRNAs showed promise as new prognostic tools for
multiple myeloma [52]. Pu et al. have also shown that
miR-221 in the plasma could be used as a potential non-
invasive prognostic biomarker for colorectal cancer [42].
Our previous study showed that eight miRNAs (miR-132,
miR-181c, miR-15a, miR-370, miR-143-3p, miR-21-5p,
miR-200a-3p, and miR-646) were expressed abnormally
in different perioperative periods of the same cervical
squamous cell carcinoma patients including pre-operative,
one week post-operative and one month post-operative,
suggesting that the levels of specific circulating miRNAs
could be useful for post-therapeutic monitoring of the
progression of this disease [22].
Recent studies revealed another important clinical appli-
cation of circulating miRNAs as predictors of response to
therapeutics, such as radiotherapy and anti-cancer agents.
For example, Summerer et al. reported that the level of cir-
culating miRNAs (miR-425-5p, miR-93-5p) changed dra-
matically in paired blood-plasma samples of head and neck
squamous cell carcinoma (HNSCC) patients prior to ther-
apy and following two days of radio chemotherapy, suggest-
ing that they might be a novel biomarker for monitoring
therapy [53]. Another study also revealed that a cluster of
highly expressed miRNAs were affected by chemotherapy
over the period from the initial to fourth cycle of treatment
in breast-cancer patients, particularly in patients with early-
stage tumors [54]. With respect to the correlation between
levels of serum miR-122 and pegylated interferon therapy
in patients with chronic hepatitis C, Su et al. described that
patients who showed complete, early virologic response
and SVR had significantly higher levels of pre-treatment
serum miR-122 than those with NR, particularly sub-
groups of patients with hepatitis C virus genotype 2 and IL-
28B rs8099917 TTgenotype. These data suggest that serum
miR-122 levels may help predict virologic responses to
pegylated IFN plus ribavirin therapy [55].
Circulating miRNAs display roles in cancer development
via cell-cell communication
In addition to the capacity of miRNAs as non-invasive
biomarkers for cancer prediction, circulating miRNA may
also play a role in the regulation of tumorigenesis. Although
the underlying mechanism by which the circulating
miRNAs function in the development and progression
of cancer remains unclear, exosomes, which are new
players in cell-cell communication and facilitate pro-
cesses including antigen presentation and hemostasis,
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showed that exosomes can fuse with the plasma membrane
leading to the release of the exosome content into the
target cell, particularly under acidic conditions.
Given that exosomes play an important role in the
regulation of cell-cell communication, exosome-derived
miRNA may be transferred from donor cells to receptor
cells and function in the target cells in diverse biological
processes. Valadi et al. were the first to report evidence
of exosome-mediated delivery of RNA and circulating
miRNAs from donor cells to neighboring cells [62]. Using
microarray, they initially detected mRNAs and small
RNAs including miRNAs in a mouse and a human mast
cell line (MC/9 and HMC-1, respectively) and in primary
bone marrow-derived mouse mast cells. They also reported
that RNA from mast-cell exosomes was transferable to
other mouse and human mast cells and that it was
functional in this new location. Chen and colleagues
also observed that some exosome-derived miRNAs
from doc-resistant BCa cells can be robustly transferred
to fluorescent sensitive cells [21]. Notably, a very recent
study reported that semen can release seminal exosome
(SE) preparations, which contain a large number of
small RNAs, such as miRNA and tRNA [63], suggesting
that SE could potentially deliver miRNAs to recipient
mucosa and that may regulate embryonic development.
These findings further suggest that exosomes containing
miRNAs can be delivered from donor cells to recipient
cells and may have the potential to be therapeutic tools to
treat cancers under diverse pathological conditions.Figure 1 Circulating miRNAs in cell-cell communication. Circulating mi
with exosome-derived miRNAs or with miRNA-binding molecules, such asExosome-derived miRNA delivered between cancer cells
and normal cells within the tumor microenvironment also
suggests that regulatory signals have the potential to play
important roles in the process of tumorigenesis [58,64,65].
An example is exosome miRNAs in acute myelocytic
leukemia (AML). Hornick et al. demonstrated that exo-
some miRNAs (miR-146, -150, 155, 210) released from
circulating leukemia cells reduced hematopoiesis by
modulating hematopoietic-stromal interactions, in part
by targeting SDF1a, SCF, and Angpt1 during AML pro-
gression in the bone-marrow microenvironment [64].
Another report discussed exosome miR-21 in glioblastoma
tumors. It showed that glioblastoma tumor cells can
release exosomes containing miR-21 and angiogenic
proteins, which are taken up by brain microvascular
endothelial cells, and induce them to transform into
cancer cells [64,66]. Yang et al. have also proposed that the
exosome-derived miR-223 was released by macrophages
and was transferred to co-cultivated SKBR3 and MDA-
MB-231 cells, suggesting a plausible mechanism of
promoting breast cancer invasion via the miR-223/
Mef2c/β-catenin pathway [65]. MiR-126, shuttled by
exosomes and targets tocxcl12, modulates adhesion and
migration in chronic myelogenous leukemia cells [67].
These findings support the hypothesis that exosomal miR-
NAs have an important role in cancer-non-cancer-cell
crosstalk within the tumor microenvironment and that
they potentially affect disease progression (Figure 1).
In addition to exosome/nanovesicle–derived miRNAs,
recent studies have also shown that circulating miRNAsRNAs display roles in cancer development via cell-cell communication
the HDL pathway, in the tumor microenvironment.
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(Figure 1). For example, Vickers et al. reported that the
uptake of miRNA high-density lipoprotein (HDL) in
plasma by recipient cells appears to be dependent on a
cell-surface HDL receptor named scavenger receptor
class B, type I (SRBI) [68], suggesting a novel possible
mechanism for the function of circulating miRNAs on the
progression of atherosclerosis or cancer. Currently, several
miRNA-binding proteins have been reported to participate
in circulating miRNA inter-or extra-cellular communication,
such as nucleophosmin1 (NPM1) [69] and Argonaute2
(Ago2) -1,-2 -3 and -4 [16,70-72].
Information on circulating miRNA in microvesicles or
biological molecules has only appeared in recent years, and
the exact role of circulating miRNAs in the development
of cancer via cell-cell communication requires further
investigation.
Therapeutic applications of circulating miRNAs in cancer
The evidence and discussion above show that circulating
miRNAs might function in the progression of tumori-
genesis via cell-cell communication, thus suggesting their
potential for serving as therapeutic tools in the future. More
interestingly, a few studies have indicated that plant miR-
NAs are found in human and animal serum and that they
are primarily acquired via food intake [73-76]. Exosome/
microvesicle-mediated delivery of miRNAs, acquired via
food intake or taken up by cells directly, could be a novel
tool for cancer therapy. Although the application of miR-
NAs in clinical practice remains a challenge (Figure 2),
there have been several reports of the development of
therapeutics based on miRNA knock-down or overexpres-
sion in mice. An example is miR-135b in colon cancer.
MiR-135b has been found to be up-regulated in mouse
embryo fibroblasts and human colorectal cancer cell lines
[77], and up-regulation of miR-135b resulted in a reduc-
tion in apoptosis and an increase in cell growth due to the
down-regulation of transforming growth factor β receptor
2 (TGFβR2), death-associated protein kinase 1 (DAPK1),Figure 2 Challenges for therapeutic implications of circulating miRNAAdenomatous Polyposis Coli (APC), and FIH, and the ac-
tivation of APC/β-catenin and SRC-PI3K pathways. This
study further reported reduced proliferation and increased
apoptosis in colorectal tumors in mice treated with anti-
miR-135b, suggesting a preclinical efficacy of miR-135b
in vivo with low toxicity. This study is the first in vivo
study of anti-miRs in the treatment of colorectal cancer.
Uchino et al. has also reported that the transurethral injec-
tion of synthetic miR-582 suppressed tumor growth and
metastasis in a mouse model of bladder cancer [78].
However, several problems have been encountered during
clinical development (Figure 2) of exosome miRNA-based
therapeutics for tumors. One of the major challenges is that
miRNAs target numerous genes in diverse types of cells,
and their functions in the complex networks of biological
pathways remain unclear. For example, miR-125 plays the
role of angel and devil in different cancer types [79]. With
respect to ovarian cancer [80], bladder cancer [81], breast
cancer [82] and some other cancers, miR-125 suppresses tu-
mors by targeting oncogenes, whereas in other types of can-
cers, such as pancreatic cancer [83], prostate cancer [84]
and oligodendroglial cancer [85], miR-125 itself acts as an
oncogene. The fact that one miRNA has varying functions
makes miRNA-based therapeutics difficult. Another major
issue is the difficulties in obtaining accurate quantification of
exosome-derived miRNAs due to different measurement
methodologies or degradation in different ways [86], and the
consequent variation might influence therapeutic effects.
Furthermore, the delivery of circulating miRNA antag-
onists or mimics as cancer therapies also encounters sev-
eral barriers, such as poor bioavailability, limited tissue
permeability and payload stability [87]. For example, the fi-
brotic microenvironment of pancreatic cancer results in
poor diffusion of therapeutic drugs and suggests that
the complex tumor microenvironment and extracellular
matrix (ECM) may hinder miRNAs from reaching the can-
cer cells [88]. Castelliet et al. also showed that the tumor-
associated macrophages can non-specifically take up and
trap miRNAs encapsulated in a delivery system [89], whichs in cancer.
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livery of miRNA by intra-tumoral injection may improve
delivery and enable effective gene-silencing and anti-
tumor effects [87]. Some reports have shown the suc-
cessful delivery of siRNA via electroporation or spher-
ical nucleic acid nanoparticle conjugates (SNA-NCs),
resulting in direct silencing of the target gene in skin
[90,91]. However, the local delivery of miRNA may en-
hance therapeutic effects only in the primary tumor
that resides in specific locations and may not be suit-
able for late-stage metastatic cancer. Thus, a method of
systemic delivery is required for cancer therapy.
Finally, the most important issue for miRNAs is clin-
ical pharmacokinetics and toxicity of miRNAs in human
organs. Recent studies have demonstrated that miRNAs
are highly water soluble and stable in serum. However,
the plasma levels of miRNAs declines rapidly following
food intake or intravenous administration, and they
spread widely through the internal environment but may
later accumulate primarily in the liver and kidney [92].
Thus, tracing and measuring circulating miRNAs in
target tumor cells and monitoring pharmacological effects
are important and challenging issues. Induction of toxicity
due to off-target effects of miRNAs or a systemic immune
response to miRNA injection may influence the pro-
gression of clinical applications. For example, following
liposome transfection of synthetic miR-145 into human
mesenchymal stem cells and human articular chondro-
cytes, Tommy and Jan observed immunological off-target
effects that were independent of toll-like receptors (TLRs)
and that were mediated by retinoic acid inducible-gene 1
(RIG-I) [93]. To overcome this immunotoxicity, miRNAs
may be delivered by exosomes or vesicles incorporated
with specific ligands or antibodies or that bind endogen-
ous receptors of cancer cells. Neesse et al. constructed
albumin-conjugated nanoparticles enriched with cysteine
(SPARC), which is robustly expressed by pancreatic
adenocarcinoma [94], and efficiently delivered the drug
to the tumor [95]. Thus, the specific exosomes containing
miRNAs may provide an alternative to enable cancer
treatment without toxicity, resulting in accurate uptake of
therapeutic miRNAs in the tumor site and suppressed
significantly the tumor regression.
Conclusions and perspectives
In this review, we summarized recent proresses on cir-
culating miRNAs from the development of detection
methods and their clinical applications as biomarkers to
their role as regulators of tumorigenesis and as cancer
therapeutics. Progresses on the biology of miRNAs greatly
enhance our understanding of their functions with respect
to basic mechanisms of oncogenesis and diagnostics and
prognostics. Clearly, cell-free miRNAs might play an
increasing role as non-invasive tools for the detection ofcancer in early stages and as biomarker to monitor prog-
nosis and response to therapy. However, knowledge on
the biological functions of extracellular miRNAs is in its
infancy. Recent studies revealed that circulating miRNAs
are derived from different sources, that they may repre-
sent varying human physiological states and that they
may play roles in the development of cancer via cell-cell
communication. With the finding that exosome miRNA
transfers are dependent on cell-cell communication, circu-
lating miRNAs demonstrate their potential for therapeutic
application in cancer.
Although great progress in the detection and function
of circulating miRNAs in cancer has been made, some
challenges exist in their clinical application and require
further investigation. The application of direct amplifica-
tion of circulating miRNAs from plasma without RNA
extraction will be a novel approach that shortens the
procedure and provides more realistic and original data
for analysis. With the development of more effective
and specific PCR enzymes for miRNA quantification,
the detection of circulating miRNAs for direct cancer
prediction in the clinic will be possible in the future.
Another major challenge is to demonstrate the exact
mechanism of circulating miRNAs derived from dead or
lysing cells or secreted from tumor cells and the mecha-
nisms of their movement, signal transmission or their
role in oncogenesis. Although recent studies have sug-
gested that circulating miRNA appears to be transported
from cell to cell via the extracellular matrix either by a
ligand-receptor system or via their ability to diffuse into
adjacent cells, or endosomal vesicles can move along
microtubulin to locate to another organelle [96-99], the
exact mechanisms deserve further investigation.
In addition to the potential of circulating miRNAs as
biomarkers for cancer prediction or prognosis, circulating
microRNAs may enable personalized cancer medicine
in future. However, several issues must be solved before
going further. One of these issues is the limited tissue
permeability of miRNAs and payload stability. The com-
mercial miRNA mimics or antagonists are unstable and
degrade easily when loaded into exosomes. Modification
of miRNAs may increase their stability and avoid RNA
enzyme activity when delivered in vivo. Thus, research
to improve the stability of exosome loading of miRNAs
without reducing pharmacological effects is urgent. In
addition, to overcome poor cancer-tissue permeability,
some exosome/vesicles incorporated with ligands or
antibodies or nanoparticles containing miRNAs may be
designed. These modified complexes may not only
enhance the permeability of the tumor but also decrease
the immunotoxicity of the complex and decrease its
induction of the human immune system. Cell-based de-
livery of miRNA mimics or antagonists may also enable
the development of cures for early-stage cancer [87].
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is also a challenge in the clinic when administering them
via food intake. Preclinical studies in animals may aid
with these investigations over the coming years. Finally,
although there are large numbers of reports on the
functions of miRNAs in the development of cancer, the
complex gene networks affected by them remains a consid-
erable problem. The complex relationships between miR-
NAs and their functional pathways must be demonstrated.
With the understanding of the origin, stability, their
role in cell-cell communication and advances in methods
to detect circulating miRNAs, we believe that, in the
future, they will become a cancer buster: From detection
to therapy.
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